{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T20:45:26Z","timestamp":1775594726224,"version":"3.50.1"},"reference-count":24,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100012399","name":"HHS | Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO100201600002C"],"award-info":[{"award-number":["HHSO100201600002C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009930","name":"Basilea Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009930","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>Ceftobiprole is an advanced cephalosporin with potent activity against Gram-positive and Gram-negative bacteria that has been approved in many European and non-European countries to treat community- and hospital-acquired pneumonia (excluding ventilator-associated pneumonia). This study reports on the activity of ceftobiprole against a large set of clinical isolates obtained from hospitalized patients in the United States in 2016 that caused serious infections, including pneumonia, bacteremia, and skin and skin structure infections.<\/jats:p>","DOI":"10.1128\/aac.01566-18","type":"journal-article","created":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T11:40:49Z","timestamp":1540899649000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":39,"title":["Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016"],"prefix":"10.1128","volume":"63","author":[{"given":"Michael A.","family":"Pfaller","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"},{"name":"University of Iowa, Iowa City, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer M.","family":"Streit","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer I.","family":"Smart","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd., Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1896-9736","authenticated-orcid":false,"given":"Kamal A.","family":"Hamed","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd., Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard R.","family":"Duncan","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02465-14"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2008.02.008"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2010.10.032"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu219"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S56616"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0273-x"},{"key":"e_1_3_3_8_2","volume-title":"Zevtera: summary of product characteristics","author":"Basilea Medical Ltd","year":"2013","unstructured":"Basilea Medical Ltd. 2013. Zevtera: summary of product characteristics. Basilea Medical Ltd., Rickmansworth, United Kingdom."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.11.005"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200809040-00004"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00029-07"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00257-08"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.10.4210-4219.2005"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05004-14"},{"key":"e_1_3_3_15_2","unstructured":"EUCAST. 2018. Breakpoint tables for interpretation of MIC's and zone diameters version 8.0. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_8.0_Breakpoint_Tables.pdf."},{"key":"e_1_3_3_16_2","volume-title":"Abstr Eur Congr Clin Microbiol Infect Dis (ECCMID), Madrid, Spain, April 21\u201324, 2018","author":"Castanheira M","year":"2018","unstructured":"Castanheira M, Smith CJ, Mendes RE, Canton R, Sader HS, Jones RN. 2018. Variations in the occurrence of ESBL, CRE, and MDR phenotypes among Enterobacteriaceae isolates: results from 20 years of the SENTRY Antimicrobial Surveillance Program, abstr P1073. Abstr Eur Congr Clin Microbiol Infect Dis (ECCMID), Madrid, Spain, April 21\u201324, 2018."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx163.901"},{"key":"e_1_3_3_18_2","volume-title":"Abstr ASM Microbe, Atlanta, GA, June 7\u201311, 2018","author":"Pfaller MA","year":"2018","unstructured":"Pfaller MA, Mendes RE, Sader HS, Streit J, Smart JI, Hamed KA, Duncan LR, Flamm RK. 2018. Antimicrobial activity of ceftobiprole when tested against Gram-positive cocci causing serious infections (2016\u20132017): endocarditis, diabetic foot, and bone\/joint infections, abstr Sunday-581. Abstr ASM Microbe, Atlanta, GA, June 7\u201311, 2018."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.12.020"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200405-644ST"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(01)00318-2"},{"key":"e_1_3_3_22_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u201411th ed","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u201411th ed. M07. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_23_2","volume-title":"Performance standards for antimicrobial susceptibility testing; 28th informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Performance standards for antimicrobial susceptibility testing; 28th informational supplement. M100-S28. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_24_2","volume-title":"Tigecycline - injection products. FDA-identified interpretive criteria","author":"U.S. Food and Drug Administration","year":"2017","unstructured":"U.S. Food and Drug Administration. 2017. Tigecycline - injection products. FDA-identified interpretive criteria. U.S. Food and Drug Administration, Silver Spring, MD. https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/ucm587585.htm. Accessed June 2018."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.7.3356-3358.2004"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01566-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01566-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:23:06Z","timestamp":1645478586000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01566-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1128\/AAC.01566-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.01566-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"2018-07-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01566-18"}}